Asia Pacific
Refine Search
Biotechnology
Over the years, cell therapy has become an essential treatment method for many incurable diseases, illnesses and injuries such as cancers, autoimmune diseases, spinal cord injuries, and neurological conditions. 20 June 2022
Biosimilars
Recently-launched Organon, a women’s health company with expertise in biosimilar commercialization, made an announcement on Monday. 14 June 2022
Biotechnology
Chinese biotech BeiGene today announced that the China National Medical Products Administration (NMPA) has approved the firm’s anti-PD-1 antibody, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC). 10 June 2022
Pharmaceutical
Japan’s largest drugmaker Takeda yesterday announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. 10 June 2022
Pharmaceutical
Chinese vaccine developer Sinovac Biotech yesterday announced that it received the World Health Organization (WHO) prequalification for its poliomyelitis vaccine (Vero Cell) inactivated Sabin strain (sIPV) on June 2, 2022. 9 June 2022
Biotechnology
Japanese drug major Astellas Pharma’s subsidiary Xyphos Biosciences and Cambridge, Massachusetts-based GO Therapeutics have entered into a strategic research collaboration and license agreement to develop novel immuno-oncology therapeutics. 2 June 2022
Biotechnology
China-based CNS drug developer SciNeuro Pharmaceuticals yesterday announced the execution of an exclusive, worldwide license and option agreement with UK pharma major GlaxoSmithKline. 2 June 2022
Pharmaceutical
In a letter to shareholders, Takeda Pharmaceutical chief executive Christophe Weber has explained that drug manufacturers may be forced to cut prices in the near term. 1 June 2022
Biotechnology
US mRNA biotech Moderna and Japan’s largest drugmaker Takeda have announced the transfer of the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax (mRNA-1273) from Takeda to Moderna as of August 1, 2022. 31 May 2022
Biotechnology
Taiwanese biotech firm AcadeMab has broken new ground in the development of immunotherapies through the development of a potentially life-saving monoclonal antibodies (MAbs) for COVID-19 patients using single B cell technology, shows the best neutralization ability (IC50 = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2 respectively. 30 May 2022
Biotechnology
Japanese drugmaker Chugai Pharmaceutical announced that it launched anti VEGF/anti Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 g/mL (faricimab [genetical recombination]) for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema (DME). 26 May 2022
Biotechnology
Research from industry analyst GlobalData highlights the growing market opportunity for Pfizer in lung cancer. 25 May 2022
Biotechnology
USA-based gene therapy and vaccine company Ocugen has seen its shares boosted by news that the US Food and Drug Administration is to lift a clinical hold on one the firm’s coronavirus vaccine program. 24 May 2022
Pharmaceutical
Shanghai-based Junshi Biosciences has announced positive results from a small trial of its COVID-19 antiviral, VV116, which compared its efficacy with Pfizer's Paxlovid (nirmatrelvir/ritonavir). 24 May 2022
Generics
About 100 generic medicines are set to be suspended from use in Europe, after a scientific panel of the European Medicines Agency reviewed evidence of irregularities at an Indian contract research organization (CRO). 23 May 2022
Pharmaceutical
The leading Australian trade body for the pharmaceutical industry, Medicines Australia, said it has alerted “hundreds of key stakeholders to get ready to engage” in the next government review of the country’s health technology assessment (HTA) system. 20 May 2022
Pharmaceutical
In an exclusive for TPL, Clover Biopharmaceuticals’ president of global R&D, Nicholas Jackson, has contributed his thoughts on what the COVID-19 pandemic has taught us. 19 May 2022
Generics
Japanese drugmaker Kyowa Kirin has decided to build a new active pharmaceutical ingredient (API) manufacturing building (HB7 Building) at its Takasaki plant that is responsible for manufacturing biopharmaceuticals. 17 May 2022
Pharmaceutical
Alzheimer’s disease (AD) is a progressive fatal neurological disorder and the most common cause of dementia primarily affecting the elderly population, with AD-associated dementia accounting for two-thirds of dementia cases in Japan. 17 May 2022
Biotechnology
The fourth of a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological. 16 May 2022
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze